{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T14:06:28Z","timestamp":1790863588250,"version":"4.1.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,12,1]],"date-time":"2003-12-01T00:00:00Z","timestamp":1070236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2003,12]]},"DOI":"10.3816\/cbc.2003.n.037","type":"journal-article","created":{"date-parts":[[2008,9,10]],"date-time":"2008-09-10T21:07:13Z","timestamp":1221080833000},"page":"318-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":101,"title":["Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer"],"prefix":"10.3816","volume":"4","author":[{"given":"Joyce A.","family":"O'Shaughnessy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CBC.2003.n.037_bib1","first-page":"23","article-title":"Cancer statistics, 2002","volume":"52","author":"Jemal","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"10.3816\/CBC.2003.n.037_bib2","series-title":"Cancer: principles and practice of oncology","first-page":"1651","article-title":"Malignant tumors of the breast","author":"Winer","year":"2001"},{"key":"10.3816\/CBC.2003.n.037_bib3","series-title":"Pharmacotherapy: a pathophysiologic approach","first-page":"2467","article-title":"Breast cancer","author":"Lindley","year":"1997"},{"key":"10.3816\/CBC.2003.n.037_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","article-title":"Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials","volume":"19","author":"Klijn","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib5","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2003.04.194","article-title":"Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group","volume":"21","author":"Mouridsen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib6","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1200\/JCO.2000.18.22.3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study","volume":"18","author":"Bonneterre","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib7","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2000.18.22.3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib8","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/annonc\/mdg362","article-title":"Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer","volume":"14","author":"Paridaens","year":"2003","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib9","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1200\/JCO.2001.19.14.3357","article-title":"Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate","volume":"19","author":"Buzdar","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib10","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1200\/JCO.2000.18.7.1399","article-title":"Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group","volume":"18","author":"Kaufmann","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib11","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1142::AID-CNCR13>3.0.CO;2-5","article-title":"Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group","volume":"83","author":"Buzdar","year":"1998","journal-title":"Cancer"},{"key":"10.3816\/CBC.2003.n.037_bib12","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1200\/JCO.2003.08.013","article-title":"Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)","volume":"21","author":"Sledge","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib13","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","article-title":"Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group","volume":"17","author":"Nabholtz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib14","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1200\/JCO.1999.17.8.2355","article-title":"Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as frontline therapy in untreated metastatic breast cancer","volume":"17","author":"Bishop","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib15","first-page":"35a","article-title":"Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC)","volume":"21","author":"Mackey","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib16","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.2002.09.002","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracyclinepretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O'Shaughnessy","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib17","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial","volume":"15","author":"Ranson","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib18","series-title":"Diseases of the breast","first-page":"669","article-title":"Treatment of metastatic disease: hormonal and chemotherapy","author":"Honig","year":"1996"},{"key":"10.3816\/CBC.2003.n.037_bib19","series-title":"Adriamycin RDF\/Adriamycin PFS (doxorubicin hydrochloride for injection) [package insert]","year":"2002"},{"key":"10.3816\/CBC.2003.n.037_bib20","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1002\/cncr.11407","article-title":"Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials","volume":"97","author":"Swain","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CBC.2003.n.037_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/gyno.2001.6355","article-title":"Anthracyclines in the treatment of gynecologic malignancies","volume":"85","author":"Maluf","year":"2002","journal-title":"Gynecol Oncol"},{"issue":"suppl 4","key":"10.3816\/CBC.2003.n.037_bib22","first-page":"1","article-title":"Anthracyclines in the treatment of cancer. An overview","volume":"54","author":"Hortobagyi","year":"1997","journal-title":"Drugs"},{"key":"10.3816\/CBC.2003.n.037_bib23","series-title":"Cancer: principles and practice of oncology","first-page":"415","article-title":"Topoisomerase interactive agents","author":"Stewart","year":"2001"},{"key":"10.3816\/CBC.2003.n.037_bib24","first-page":"670","article-title":"The anthracyclines: will we ever find a better doxorubicin?","volume":"19","author":"Weiss","year":"1992","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib25","first-page":"431","article-title":"Liposomal anthracyclines","volume":"8","author":"Gabizon","year":"1994","journal-title":"Hematol Oncol Clin North Am"},{"issue":"suppl 4","key":"10.3816\/CBC.2003.n.037_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2165\/00003495-199700544-00005","article-title":"Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours","volume":"54","author":"Gabizon","year":"1997","journal-title":"Drugs"},{"key":"10.3816\/CBC.2003.n.037_bib27","first-page":"987","article-title":"Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes","volume":"54","author":"Gabizon","year":"1994","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2003.n.037_bib28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1081\/CNV-100103136","article-title":"Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy","volume":"19","author":"Gabizon","year":"2001","journal-title":"Cancer Invest"},{"key":"10.3816\/CBC.2003.n.037_bib29","first-page":"6371","article-title":"Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies","volume":"50","author":"Gabizon","year":"1990","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2003.n.037_bib30","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/1061186021000043061","article-title":"Liposomal drug carrier systems in cancer chemotherapy: current status and future prospects","volume":"10","author":"Gabizon","year":"2002","journal-title":"J Drug Target"},{"key":"10.3816\/CBC.2003.n.037_bib31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0168-3659(97)00237-X","article-title":"Delivery of molecular and cellular medicine to solid tumors","volume":"53","author":"Jain","year":"1998","journal-title":"J Control Release"},{"key":"10.3816\/CBC.2003.n.037_bib32","series-title":"Medical applications of liposomes","first-page":"638","article-title":"Clinical pharmacology and anti-tumor efficacy of Doxil (pegylated liposomal doxorubicin)","author":"Martin","year":"1998"},{"key":"10.3816\/CBC.2003.n.037_bib33","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.1073\/pnas.85.18.6949","article-title":"Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors","volume":"85","author":"Gabizon","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.3816\/CBC.2003.n.037_bib34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0169-409X(96)00476-0","article-title":"Long-circulating liposomes for drug delivery in cancer therapy: a review of biodistribution studies in tumor-bearing animals","volume":"24","author":"Gabizon","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"10.3816\/CBC.2003.n.037_bib35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/bjc.1997.84","article-title":"Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma","volume":"75","author":"Vaage","year":"1997","journal-title":"Br J Cancer"},{"key":"10.3816\/CBC.2003.n.037_bib36","first-page":"243","article-title":"Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes","volume":"7","author":"Harrington","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2003.n.037_bib37","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1200\/JCO.1999.17.11.3512","article-title":"Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer","volume":"17","author":"Koukourakis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/028418600430789","article-title":"High intratumoral accumulation of stealth liposomal doxorubicin in sarcomas\u2013rationale for combination with radiotherapy","volume":"39","author":"Koukourakis","year":"2000","journal-title":"Acta Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib39","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/j.1552-4604.1996.tb04152.x","article-title":"Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDSrelated Kaposi's sarcoma","volume":"36","author":"Northfelt","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.3816\/CBC.2003.n.037_bib40","first-page":"11","article-title":"Pegylated liposomal doxorubicin: scientific rationale and preclinical pharmacology","volume":"11","author":"Martin","year":"1997","journal-title":"Oncology"},{"key":"10.3816\/CBC.2003.n.037_bib41","series-title":"Doxil (doxorubicin HCI liposome injection) [package insert]","year":"2001"},{"key":"10.3816\/CBC.2003.n.037_bib42","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"10.3816\/CBC.2003.n.037_bib43","unstructured":"Wigler N, O'Brien M, Rosso R, et al. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (Caelyx\/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Presented at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002."},{"key":"10.3816\/CBC.2003.n.037_bib44","first-page":"190b","article-title":"Phase III trial of pegylated liposomal doxorubicin (Caelyx\/Doxil) for the treatment of patients with advanced breast cancer who have failed a prior taxanecontaining chemotherapy regimen","volume":"20","author":"Keller","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib45","first-page":"324","article-title":"Doxil and intravenous cyclophosphamide as first-line therapy for patients with metastatic breast cancer (MBC): interim results of an ongoing pilot trial","volume":"50","author":"Overmoyer","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.3816\/CBC.2003.n.037_bib46","first-page":"116a","article-title":"Phase II study of weekly paclitaxel (Taxol) and liposomal doxorubicin (Doxil) in patients with locally advanced and metastatic breast cancer","volume":"19","author":"Jones","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib47","first-page":"49","article-title":"Multicentre phase II study with pegylated liposomal doxorubicin (PLD) and paclitaxel (T) as first line therapy in patients (pts) with advanced breast cancer (ABC)","volume":"22","author":"Vorobiof","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib48","first-page":"1817","article-title":"Paclitaxel and liposomal doxorubicin (Caelyx) combination in advanced breast cancer patients: a phase II study","volume":"10","author":"Rigatos","year":"2003","journal-title":"Oncol Rep"},{"key":"10.3816\/CBC.2003.n.037_bib49","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.2001.19.12.3117","article-title":"Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer","volume":"19","author":"Sparano","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib50","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/cncr.11547","article-title":"Phase I dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies","volume":"98","author":"Fracasso","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CBC.2003.n.037_bib51","first-page":"58","article-title":"Pegylated liposomal doxorubicin (PLD) and docetaxel (D) as first-line treatment in metastatic breast cancer (MBC)","volume":"22","author":"Alexopoulous","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib52","first-page":"74","article-title":"A phase II trial of docetaxel (D) and liposomal doxorubicin (LD) as 1st line treatment in metastatic breast cancer (MBC)","volume":"22","author":"Athanassiou","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib53","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1200\/JCO.2001.19.6.1716","article-title":"Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer","volume":"19","author":"Rivera","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib54","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1200\/JCO.2003.03.111","article-title":"Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine in patients with metastatic breast cancer","volume":"21","author":"Rivera","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib55","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/0360-3016(94)90572-X","article-title":"Hyperthermia induces doxorubicin release from long-circulating liposomes and enhances their anti-tumor efficacy","volume":"29","author":"Ning","year":"1994","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.3816\/CBC.2003.n.037_bib56","first-page":"2186","article-title":"Liposomes and hyperthermia in mice: increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes","volume":"54","author":"Huang","year":"1994","journal-title":"Cancer Res"},{"key":"10.3816\/CBC.2003.n.037_bib57","first-page":"374","article-title":"Liposomal doxorubicin in conjunction with reirradiation and local hyperthermia treatment in recurrent breast cancer: a phase I\/II trial","volume":"8","author":"Kouloulias","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CBC.2003.n.037_bib58","first-page":"47a","article-title":"Hyperthermia (HT) + Doxil significantly enhances drug delivery and efficacy in metastatic breast cancer of the chest wall (CW): a phase I\/II study","volume":"20","author":"Park","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib59","first-page":"166","article-title":"Pegylated liposomal doxorubicin in combination with hyperthermia for treatment of skin metastases of breast carcinoma: a case report","volume":"24","author":"Dvorak","year":"2001","journal-title":"Onkologie"},{"key":"10.3816\/CBC.2003.n.037_bib60","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00004836-200201000-00020","article-title":"Pegylated liposomal doxorubicin in combination with hyperthermia in the treatment of a case of advanced hepatocellular carcinoma","volume":"34","author":"Dvorak","year":"2002","journal-title":"J Clin Gastroenterol"},{"key":"10.3816\/CBC.2003.n.037_bib61","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1093\/annonc\/mdf284","article-title":"Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group","volume":"13","author":"Gogas","year":"2002","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib62","first-page":"70A","article-title":"Phase II study with the combination of pegylated liposomal doxorubicin (Caelyx) and cyclophosphamide (CC) in locally advanced breast cancer (LABC)","volume":"21","author":"Srimuninnimit","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib63","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1023\/A:1008365716693","article-title":"Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg\/m2","volume":"11","author":"Safra","year":"2000","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib64","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1023\/A:1008216430806","article-title":"The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin","volume":"9","author":"Berry","year":"1998","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib65","first-page":"763","article-title":"Cardiac safety of pegylated liposomal doxorubicin demonstrated by endomyocardial biopsy in patients with advanced malignancies","volume":"22","author":"Gabizon","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib66","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1006\/gyno.2001.6272","article-title":"Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages","volume":"82","author":"Rose","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib67","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/gyno.2000.5980","article-title":"The clinical utility of liposomal doxorubicin in recurrent ovarian cancer","volume":"81","author":"Campos","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0749-2081(03)00059-7","article-title":"Prevention and treatment of adverse effects related to chemotherapy for recurrent ovarian cancer","volume":"19","author":"Edwards","year":"2003","journal-title":"Semin Oncol Nurs"},{"key":"10.3816\/CBC.2003.n.037_bib69","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00128071-200001040-00004","article-title":"Antineoplastic therapy-induced palmar plantar erythrodysesthesia (\u2018hand-foot\u2019) syndrome. Incidence, recognition and management","volume":"1","author":"Nagore","year":"2000","journal-title":"Am J Clin Dermatol"},{"key":"10.3816\/CBC.2003.n.037_bib70","first-page":"238a","article-title":"Treatment of palmarplantar erythrodysthesia with pyridoxine or ergotamine: effect on efficacy of Doxil in Lewis lung carcinoma","volume":"17","author":"Colbern","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 2","key":"10.3816\/CBC.2003.n.037_bib71","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1081\/CNV-120014883","article-title":"Pegylated liposomal doxorubicin (Doxil) for metastatic breast cancer: the Cancer Research Network, Inc., experience","volume":"20","author":"Perez","year":"2002","journal-title":"Cancer Invest"},{"key":"10.3816\/CBC.2003.n.037_bib72","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/annonc\/mdg374","article-title":"Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions","volume":"14","author":"Chanan-Khan","year":"2003","journal-title":"Ann Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib73","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2002.20.3.719","article-title":"Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer","volume":"20","author":"Vogel","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib74","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.1999.17.9.2639","article-title":"Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease","volume":"17","author":"Cobleigh","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib75","first-page":"78","article-title":"Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2\/neu-overexpressing metastatic breast cancer","volume":"26","author":"Baselga","year":"1999","journal-title":"Semin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib76","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"10.3816\/CBC.2003.n.037_bib77","first-page":"55a","article-title":"TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis","volume":"21","author":"Theodoulou","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib78","first-page":"18","article-title":"Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer (MBC): preliminary results of Eastern Cooperative Oncology Group trial 3198","volume":"22","author":"Wolff","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.3816\/CBC.2003.n.037_bib79","first-page":"84","article-title":"Sequential treatment with anthracyclines and taxane with\/without trastuzumab for metastatic breast cancer patients","volume":"22","author":"Aramendia","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 2","key":"10.3816\/CBC.2003.n.037_bib80","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1634\/theoncologist.8-suppl_2-25","article-title":"Liposomal anthracyclines and new treatment approaches for breast cancer","volume":"8","author":"Wolff","year":"2003","journal-title":"Oncologist"},{"key":"10.3816\/CBC.2003.n.037_bib81","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911709442?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820911709442?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:11:48Z","timestamp":1761513108000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820911709442"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,12]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,12]]}},"alternative-id":["S1526820911709442"],"URL":"https:\/\/doi.org\/10.3816\/cbc.2003.n.037","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2003,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CBC.2003.n.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}